The European Patent Office (EPO) has published patent application EP4499622A1, filed by Lunella Biotech, Inc. The application, titled '2-[(2-OXO-4-PHENYL-2H-CHROMEN-7-YL)OXY] PROPANAMIDO DERIVATIVES', details novel chemical compounds and their synthesis. The publication date is March 18, 2026, and it includes classifications related to organic chemistry and pharmaceutical applications, specifically A61P 35/00 (treatment of cancer).

This publication represents the grant of a patent, not a regulatory requirement for companies. It grants exclusive rights to Lunella Biotech, Inc. for the patented inventions within the designated European states. Companies operating in the pharmaceutical sector should be aware of this patent for competitive intelligence and to avoid infringement if they are developing similar compounds or therapies.